Stock Track | Septerna Soars 5.25% as Wells Fargo Upgrades to Overweight, Citing Promising Drug Pipeline

Stock Track

Nov 14

Septerna, Inc. (SEPN) shares are soaring 5.25% in Friday's pre-market trading following a significant upgrade from Wells Fargo. The investment bank raised its rating on the drug developer from Equal Weight to Overweight and substantially increased its price target from $18 to $28, signaling strong confidence in the company's future prospects.

The upgrade is primarily driven by Wells Fargo's optimism about Septerna's drug pipeline, particularly the SEP-479 compound, an oral PTH1R agonist. Analysts expressed confidence in the safety profile of SEP-479 and its differentiation from the company's previous programs. A key factor in this assessment is a study conducted on cynomolgus monkeys, which suggests that SEP-479 does not have the bilirubin issues associated with the company's previous drug candidate, SEP-786.

Investors are also eyeing several near-term catalysts for Septerna. Wells Fargo highlighted the upcoming phase 1 results for the company's SEP-631 compound as an important milestone. Additionally, data from the SEP-479 compound is expected in late 2026, potentially providing further upside for the stock. These developments are seen as crucial for Septerna's growth trajectory, prompting the significant upgrade and driving today's stock surge.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/1172365512"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1172365512\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1172365512?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-14 22:32","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1172365512","market":"us","top_or_hot":-1,"title":"Stock Track | Septerna Soars 5.25% as Wells Fargo Upgrades to Overweight, Citing Promising Drug Pipeline","media":"Stock Track","content":"<p>Septerna, Inc. (SEPN) shares are soaring 5.25% in Friday's pre-market trading following a significant upgrade from Wells Fargo. The investment bank raised its rating on the drug developer from Equal Weight to Overweight and substantially increased its price target from $18 to $28, signaling strong confidence in the company's future prospects.</p>\n\n<p>The upgrade is primarily driven by Wells Fargo's optimism about Septerna's drug pipeline, particularly the SEP-479 compound, an oral PTH1R agonist. Analysts expressed confidence in the safety profile of SEP-479 and its differentiation from the company's previous programs. A key factor in this assessment is a study conducted on cynomolgus monkeys, which suggests that SEP-479 does not have the bilirubin issues associated with the company's previous drug candidate, SEP-786.</p>\n\n<p>Investors are also eyeing several near-term catalysts for Septerna. Wells Fargo highlighted the upcoming phase 1 results for the company's SEP-631 compound as an important milestone. Additionally, data from the SEP-479 compound is expected in late 2026, potentially providing further upside for the stock. These developments are seen as crucial for Septerna's growth trajectory, prompting the significant upgrade and driving today's stock surge.</p>","source":"ai_movement_en","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Stock Track | Septerna Soars 5.25% as Wells Fargo Upgrades to Overweight, Citing Promising Drug Pipeline</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nStock Track | Septerna Soars 5.25% as Wells Fargo Upgrades to Overweight, Citing Promising Drug Pipeline\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1086803395\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock Track </p>\n<p class=\"h-time\">2025-11-14 22:32</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Septerna, Inc. (SEPN) shares are soaring 5.25% in Friday's pre-market trading following a significant upgrade from Wells Fargo. The investment bank raised its rating on the drug developer from Equal Weight to Overweight and substantially increased its price target from $18 to $28, signaling strong confidence in the company's future prospects.</p>\n\n<p>The upgrade is primarily driven by Wells Fargo's optimism about Septerna's drug pipeline, particularly the SEP-479 compound, an oral PTH1R agonist. Analysts expressed confidence in the safety profile of SEP-479 and its differentiation from the company's previous programs. A key factor in this assessment is a study conducted on cynomolgus monkeys, which suggests that SEP-479 does not have the bilirubin issues associated with the company's previous drug candidate, SEP-786.</p>\n\n<p>Investors are also eyeing several near-term catalysts for Septerna. Wells Fargo highlighted the upcoming phase 1 results for the company's SEP-631 compound as an important milestone. Additionally, data from the SEP-479 compound is expected in late 2026, potentially providing further upside for the stock. These developments are seen as crucial for Septerna's growth trajectory, prompting the significant upgrade and driving today's stock surge.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"SEPN","symbol_name":"Septerna, Inc.","start_time":0,"source_url":"","article_id":"1172365512","we_media_id":"1086803395","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1172365512","pubTimestamp":1763130743,"columns":[],"sourceInfo":{"source_id":"ai_movement_en","name":"Stock Track"},"weMediaInfo":{"media_name":"Stock Track","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1086803395","head_image":"https://static.tigerbbs.com/a81accab1e7ee4144dc051f71903a390"},"summary":"Septerna, Inc. (SEPN) shares are soaring 5.25% in Friday's pre-market trading following a significant upgrade from Wells Fargo. The investment bank raised its rating on the drug developer from Equal...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"SEPN":"Septerna, Inc."},"translate_title":"个股追踪|Septerna飙升5.25%，富国银行上调跑赢大盘评级，称药物管线前景看好","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SEPN":1},"content_text":"Septerna, Inc. (SEPN) shares are soaring 5.25% in Friday's pre-market trading following a significant upgrade from Wells Fargo. The investment bank raised its rating on the drug developer from Equal Weight to Overweight and substantially increased its price target from $18 to $28, signaling strong confidence in the company's future prospects.\nThe upgrade is primarily driven by Wells Fargo's optimism about Septerna's drug pipeline, particularly the SEP-479 compound, an oral PTH1R agonist. Analysts expressed confidence in the safety profile of SEP-479 and its differentiation from the company's previous programs. A key factor in this assessment is a study conducted on cynomolgus monkeys, which suggests that SEP-479 does not have the bilirubin issues associated with the company's previous drug candidate, SEP-786.\nInvestors are also eyeing several near-term catalysts for Septerna. Wells Fargo highlighted the upcoming phase 1 results for the company's SEP-631 compound as an important milestone. Additionally, data from the SEP-479 compound is expected in late 2026, potentially providing further upside for the stock. These developments are seen as crucial for Septerna's growth trajectory, prompting the significant upgrade and driving today's stock surge.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"movement","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}